Paper Details

  1. Home
  2. Paper Details

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.

Author: AdlerMichael, DeltenrePierre, HenrionJean, MathurinPhilippe, MorenoChristophe, PawlotskyJean-Michel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

24 weeks of pegylated interferon alpha and ribavirin therapy is less effective than 48 weeks in HCV-1 patients with rapid viral decline. Shorter therapy should only be considered for patients with low baseline viral load.
Paper Details　
Original Abstract of the Article :
BACKGROUND & AIMS: In hepatitis C virus genotype 1 (HCV-1) patients with a rapid viral decline within the first month of therapy, a 24-week course of pegylated interferon (PEG-IFN) alpha and ribavirin treatment has been claimed to be as efficient as the standard 48-week duration. METHODS: We perfor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jhep.2009.10.003

データ提供：米国国立医学図書館（NLM）

Shortened Treatment Duration for Hepatitis C: Finding a Shortcut in the Desert of Viral Infections

Hepatitis C virus (HCV) infection, a challenging viral illness, requires effective treatment strategies. This study investigates the feasibility of shortening treatment duration for treatment-naive genotype 1 HCV patients who achieve a rapid virological response (RVR) within the first month of therapy. The researchers conducted a meta-analysis of randomized controlled trials comparing shorter treatment durations to the standard 48-week course of pegylated interferon (PEG-IFN) alpha and ribavirin.

Shortened Treatment Duration: A Potential Oasis in the Desert of Viral Infections

This study explores the potential for shortening treatment duration for certain HCV patients. The researchers found that while shortening treatment duration can be effective for some individuals, it may increase the risk of relapse, especially for those with high baseline viral loads.

Navigating the Desert of Viral Infections with Caution

This research highlights the importance of individualized treatment approaches for HCV infection. Healthcare providers must carefully consider factors like viral load and treatment response to determine the optimal treatment duration for each patient.

Dr.Camel's Conclusion

This study offers a glimpse into the evolving landscape of HCV treatment. While shortening treatment duration can be beneficial for some individuals, it's essential to tailor treatment plans based on individual characteristics to ensure optimal outcomes and minimize the risk of relapse.

Date :
  1. Date Completed 2010-09-16
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

19931204

DOI: Digital Object Identifier

10.1016/j.jhep.2009.10.003

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.